Dynamic Wealth Report | Monday, December 24, 2012
A simple five-paragraph rule adopted by the SEC in 2003 is quietly making a small group of investors very rich...
And there's no good reason why you can't join them.
In this report you'll find the 3 things you can do RIGHT NOW to jump on this trend before it's too late.
Discover this loophole for free, right here.
HALO Gearing Up For A Rebound In 2013?
By Robert Morris
 Investors holding shares of biotech Halozyme Therapeutics (HALO) awoke to excellent news Friday morning. The company announced it had entered into a worldwide collaboration and licensing agreement with Pfizer (PFE).
The deal gives Pfizer a global license to develop and market products using Halozyme's revolutionary Enhanze drug delivery technology. I'll tell you all about this exciting technology in just a moment.
In exchange, HALO received an upfront payment of $8 million with the potential to earn additional fees of up to $507 million. The biotech can also earn royalties on any future sales of drugs developed through the partnership.
As you can see, HALO soared on the news!
After closing on Thursday at $5.52, the stock opened at $6.36 Friday morning and never looked back. It eventually closed at $7.01 for a one-day gain of 27%.
The investment by a major global drug maker clearly gave HALO a much needed shot in the arm.
In August, the stock had hit a 52-week low of $3.82, punctuating a 70% decline from the high of $13.50 set in March. And while HALO had bounced off the lows prior to the Pfizer deal, it was still posting a hefty 40% loss for the year.
Why was HALO struggling?
The stock had plunged after the FDA rejected an immune deficiency treatment developed by Baxter (BAX) that includes HALO's drug-delivery enzyme rHuPH20. Regulators are concerned rHuPH20 may have an impact on reproduction, development, and fertility.
As such, the drug is on hold until the two companies can provide pre-clinical data on rHuPH20.
No question about it, the Pfizer deal couldn't have come at a better time for HALO.
The deal provides renewed credibility for Halozyme's Enhanze technology. You see, Enhanze is based on rHuPH20, HALO's patented recombinant human hyaluronidase enzyme.
How does rHuPH20 work?
The enzyme temporarily degrades hyaluronan, a structural component of the subcutaneous space that is just beneath the outside surface of the skin. This temporary degradation in turn provides an opportunistic window for the improved subcutaneous delivery of injectable biologics.
Why is this so important?
By using rHuPH20, many therapeutics that could normally only be injected intravenously can now be given with a subcutaneous injection. This change in delivery can often improve patient convenience, boost efficacy, extend the product lifecycle, and reduce cost.
The possibilities for rHuPH20 are simply mind-boggling.
And Pfizer isn't the only major drug maker excited about its potential.
Roche (RHBBY) is currently partnered with HALO to develop subcutaneous versions of their approved drugs for breast cancer, non-Hodgkins lymphoma, and rheumatoid arthritis. And Viropharma (VPHM) is working with HALO on a subcutaneous formulation of Cinryze, an approved treatment for hereditary angiodema.
While it remains to be seen, Friday's rally could be just the beginning of a longer-term uptrend in HALO. Take a closer look at this intriguing biotech for your own portfolio.
Profitably Yours,
Robert Morris
A 'Sneaky' Way To Easily And Consistently Profit From Sector ETFs...
Everyone knows there's a lot of money to be made if you happen to invest into a hot sector at the right time.
The problem has always been how to know which sectors are about to take off... until now!
You see here's an obscure document published by the US Government that acts almost like a crystal ball tipping you off to sectors of the economy that are about to get red-hot!
Click here to see how it works...
| | | | | | | Copyright 2012 Hyperion Financial Group, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the Dynamic Wealth Report website and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of Hyperion Financial Group, LLC.
LEGAL DISCLAIMER: Neither Hyperion Financial Group LLC nor any of it's employees, contractors or officers are registered investment advisors or a Broker/Dealer. As such, Hyperion Financial Group, LLC does not offer or provide personalized investment advice. Although Hyperion Financial Group, LLC employees and contractors may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees or contractors to you should be considered personalized investment advice.
Owners and writers may have positions in the securities that are discussed. However, no associated employees or contractors may intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. We accept no compensation from any companies mentioned in our reports.
Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your financial advisor. | |
No comments:
Post a Comment
Keep a civil tongue.